Skip to main content

Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

SAN DIEGO, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, which takes place November 16th, 2023, at the Westin New York Grand Central Hotel in New York City. John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will present at 9:30 AM ET. Interested parties may access the webcast of the presentation using a link on Exagen’s website at https://investors.exagen.com/events.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com 
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.69
-10.30 (-4.42%)
AAPL  275.91
-0.58 (-0.21%)
AMD  192.50
-7.69 (-3.84%)
BAC  54.94
-0.44 (-0.79%)
GOOG  331.33
-2.01 (-0.60%)
META  670.21
+1.22 (0.18%)
MSFT  393.67
-20.52 (-4.95%)
NVDA  171.88
-2.31 (-1.33%)
ORCL  136.48
-10.19 (-6.95%)
TSLA  397.21
-8.80 (-2.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.